All data are based on the daily closing price as of July 18, 2025
a

ABL Bio

298380.KQ
53.40 USD
0.90
+1.71%

Overview

Last close
53.40 usd
Market cap
2.59B usd
52 week high
60.20 usd
52 week low
14.93 usd
Target price
50.33 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
130.4945
Price/Book Value
25.7279
Enterprise Value
2.55B usd
EV/Revenue
128.2385
EV/EBITDA
-32.1061

Key financials

Revenue TTM
19.87M usd
Gross Profit TTM
19.83M usd
EBITDA TTM
-51.61M usd
Earnings per Share
-1.07 usd
Dividend
N/A usd
Total assets
142.99M usd
Net debt
13.42M usd

About

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea.
  • Symbol
    298380.KQ
  • Exchange
    KQ
  • Isin
    KR7298380007
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Dr. Sang Hoon Lee Ph.D.
  • Headquarter
    Seongnam-si
  • Web site
    https://www.ablbio.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top